We are really excited to be attending ISPOR 2025 in Montreal, Canada, in May! Below you will find information on our attendees, details of our booth in the conference exhibition hall, and a summary of the research we are proud to have contributed to the conference. Check back here after the conference to see our key insights from our time in Montreal.
We will be located at Booth 700 within the main exhibition hall, where you’ll always be able to find someone from Costello Medical and learn more about our company and services. We look forward to meeting with you! If you would like to book a meeting with us ahead of time, please feel free to reach out to Molly Atkinson or get in touch.
We’re delighted to have a team of 10 people attending the conference, including experts in our Evidence Development (Literature Reviews, Real-World Evidence, and Statistics), and Value & Access (HTA, Health Economics, and Market Access) services, representatives from our dedicated Rare Diseases team, and our Head of Growth and External Engagement.
Evidence Development
Value & Access
Rare Diseases
External Engagement
We will have a number of key focuses for the conference, including the ongoing impact of the Inflation Reduction Act (IRA), and the potential for technical innovation and artificial intelligence (AI) to facilitate advances in health economics and outcomes research (HEOR).
The introduction of the IRA has had a huge impact across the US healthcare industry, and the ongoing influence of these changes is anticipated to be one of ISPOR 2025’s hot topics.
Our teams across Evidence Development and Value & Access have been reflecting on the key challenges and opportunities, and have been working alongside our clients to develop compelling evidence packages in support of the value of products that may be selected for negotiation. Our Rare Diseases team have also been focusing on the impact of the IRA on investment and innovation in the rare diseases space more broadly, with an issue panel to be presented at ISPOR 2025 focusing specifically on this topic, which is summarised below.
If you have any questions, please don’t hesitate to reach out to .
The potential for technical innovation and AI to facilitate advances in HEOR is an important research interest for us at Costello Medical, and we are excited to engage in sessions that delve into this topic at ISPOR 2025.
Our HEOR-focused teams have conducted pilots to explore opportunities for innovation, including the use of generative AI (GenAI) to support value-focused writing and insight gathering to inform HTA strategy. We are also excited to present research at the conference summarising a prompt engineering and testing project we conducted to assess the usefulness and accuracy of genAI in extractions for economic reviews.
If you have any questions about our AI strategy, or would be interested in collaborating with us, please don’t hesitate to reach out to Helen Chambers or any of our conference attendees.
We are delighted to be hosting an issue panel at ISPOR 2025. The details of this session can be found below:
Following the IRA’s 2022 roll-out, there was a knee-jerk reaction by some stakeholders to suspend clinical programmes in rare diseases. The National Organisation for Rare Disorders subsequently declared in an open 2023 letter to the Centers for Medicare and Medicaid Services (CMS) that the IRA could inadvertently reduce investment and, subsequently, access to rare disease therapies. Three years after the IRA’s introduction, this issue panel will address to what extent these concerns will impact investment, access, and pricing in rare diseases.
We are delighted to be presenting 6 research posters at ISPOR 2025. The titles of our research are listed below, alongside the poster session dates and times.
Wednesday
14 May
Thursday
15 May
Friday
16 May
Our conference attendees will prepare commentaries on a variety of specific topics from ISPOR 2025. Watch this space for these commentaries soon after the conference!
